article thumbnail

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Drug Discovery World

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18 s submission.

Licensing 246
article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to get the biopharma deal you want

Drug Discovery World

When the science lines up, execution of BD goals can enable time-appropriate returns to investors, lengthen the runway (time to cash out), and expand the reach of core technologies beyond programs that can be carried out internally. For pharmas, new programs and portfolios from biotech companies offer a way to augment internal research.

article thumbnail

Expanded Access to Rabies Plasmids

addgene Blog

Addgene is excited to announce we now offer an export license application for rabies materials! The export license, if granted, allows us to ship rabies plasmids and viral vectors containing genetic elements from rabies plasmids to international requestors.

article thumbnail

UCL accelerates research of relapse in childhood blood cancer 

Drug Discovery World

However, 50% of responding patients will relapse either due to evolution of CD19 negative disease or early loss of CAR T-cells so that only around 40% of patients are cured by the currently licensed CAR T-cell therapies. There is thus a clear unmet need to develop novel CAR T-cell products with improved efficacy.

Research 130
article thumbnail

UK-Norway partnership to speed up cancer drug discovery

Drug Discovery World

Potential projects will be evaluated through the CDD’s review process, including both an internal assessment and an external review by its New Agents Committee. Cancer Research UK’s innovation unit, Cancer Research Horizons, will lead on any subsequent later-stage development which may include out-licensing to a suitable third party.

Drugs 130
article thumbnail

Collaborators investigate novel T-cell receptor therapy

Drug Discovery World

Elicera Therapeutics has the right to utilise the data in its internal project development as well as commercialisation activities, including licensing agreements. The studies will evaluate the therapy’s effect on tumour growth and activation of other immune cells in the tumour microenvironment.

Therapies 130